<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082936</url>
  </required_header>
  <id_info>
    <org_study_id>IGM-2323-001</org_study_id>
    <nct_id>NCT04082936</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IGM Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IGM Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study of IGM-2323 in adult subjects with relapsed or refractory B-cell&#xD;
      Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage and a dose-expansion&#xD;
      stage where subjects will be enrolled into indication-specific expansion cohorts. IGM-2323&#xD;
      will be administered intravenously (IV).&#xD;
&#xD;
      Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical&#xD;
      Monitor approval during the Dose-Escalation Phase of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGM-2323 is an engineered bispecific IgM antibody for the treatment of patients with&#xD;
      CD20-positive cancers. It contains ten high affinity binding domains for CD20, and one&#xD;
      binding domain for CD3. IGM-2323 is able to eliminate CD20-positive lymphoma cells by&#xD;
      engaging T-cells and lymphoma cells, leading to T-cell dependent cellular cytotoxicity.&#xD;
      Additionally, IGM-2323 is also able to eliminate lymphoma cells by recruiting complement to&#xD;
      the surface of lymphoma cells, leading to complement dependent cytotoxicity.&#xD;
&#xD;
      In our preclinical studies, we observed activity against rituximab resistant cells carrying&#xD;
      low levels of CD20. We have also observed much lower cytokine release with IGM-2323 relative&#xD;
      to comparable IgG format bispecific T-cell engaging antibodies, which is expected to result&#xD;
      in reduced risk of the serious adverse effects from cytokine release syndrome (CRS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Frequency of Adverse Events</measure>
    <time_frame>Baseline through approximately 30 days after last study treatment</time_frame>
    <description>Percentage of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>Percentage of measurable disease in subjects who have achieved either complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>measured from time of initial response until documented tumor progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>DLBCL</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose-Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive IGM-2323 via intravenous (IV) infusion on Days 1, 8, and 15, of 21-day cycles. Subjects will be treated with 4 cycles (3 weeks each). Subjects benefiting from therapy can receive up to 8 cycles or longer with good response. Dose escalation will be guided by the observed incidence of DLTs at each dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose-Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive IGM-2323 via intravenous (IV) infusion at a RP2D dose and schedule to be determined after reviewing all available response and safety data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGM-2323</intervention_name>
    <description>Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.</description>
    <arm_group_label>Part 1: Dose-Escalation Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGM-2323</intervention_name>
    <description>Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.</description>
    <arm_group_label>Part 2: Dose-Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age: ECOG PS 0 or 1&#xD;
&#xD;
          -  Relapsed or Refractory Follicular Lymphoma (FL), and Diffuse Large B-cell Lymphoma&#xD;
             (DLBCL), Mantle cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) in dose escalation&#xD;
&#xD;
          -  Relapsed or refractory to at least two prior systemic treatment regimens (must include&#xD;
             anti-CD20 chemo-immunotherapy regimen).&#xD;
&#xD;
          -  At least one bi-dimensionally measurable lesion (&gt;1.5cm in it's longest dimension by&#xD;
             computerized tomography (CT scan)&#xD;
&#xD;
          -  Good organ function&#xD;
&#xD;
          -  Not eligible for autologous stem cell transplant (DLBCL subjects), due to&#xD;
             chemoresistant disease, medically unfit (organ function), or unwilling.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior allogeneic transplant&#xD;
&#xD;
          -  ASCT within 100 days prior to the first IGM-2323 administration.&#xD;
&#xD;
          -  Prior treatment with CD3 engaging bispecific antibodies.&#xD;
&#xD;
          -  Lack of response to prior treatment with CAR-T therapy, subjects with less than 3&#xD;
             months from prior CAR-T therapy to first dose of IGM-2323, and prior CAR-T therapy&#xD;
             only allowed with Medical Monitor approval.&#xD;
&#xD;
          -  Concurrent serious co-morbidities that could limit patients' full participation and&#xD;
             compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibrahim Qazi</last_name>
    <role>Study Director</role>
    <affiliation>IGM Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Sison</last_name>
    <phone>510-329-9857</phone>
    <email>clinicaltrials@IGMbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSKCC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutch</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Resaerch</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>relapsed or refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin M</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

